As of 30 September 2017, Probiodrug held EUR 11.70 million in cash and cash equivalents, providing according to present projections a cash reach through 2018

HALLE (SAALE), Germany, 30 November 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announces its third quarter business update for the period ending 30 September 2017, in the form of an interim management report.
The interim management report for the third quarter 2017 is available to download on the company website (